Company: GANX
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001104659-25-068103
Chunk: 23

Company: Gain Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 23
---
arrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction.

Exchange Listing . We do not plan to apply to list the Pre-Funded Warrants on the Nasdaq Global Market, any other national securities exchange or any other nationally recognized trading system.

Rights as a Stockholder. Except as otherwise provided in the Pre-Funded Warrants or by virtue of such holder’s ownership of, the holders of the Pre-Funded Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their Pre-Funded Warrants.

Warrant Agent. We will act as warrant agent for the Pre-Funded Warrants.

<div align='center'>S-15</div>

TABLE OF CONTENTS

#### Description of Common Warrants
The material terms and provisions of the Common Warrants being issued in this offering are summarized below. The following description is subject to, and qualified in its entirety by, the warrant agency agreement between us and the Warrant Agent (the “Warrant Agency Agreement”) and the form of Common Warrant each of which will be filed as an exhibit to a Current Report on Form 8-K to be filed by us with the SEC in connection with this offering. You should review the Warrant Agency Agreement and the form of Common Warrant for a complete description of the terms and conditions applicable to the Common Warrant.

Exercise Price . The initial exercise price is $ per share of common stock. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock.

Exercisability . The Common Warrants are exercisable at any time after the date of issuance, in whole or in part, and at any time up to the date that is five years from the date of issuance, at which time any unexercised Common Warrants will expire and cease to be exercisable. The Common Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise. If a registration statement registering the issuance of the shares of common stock underlying the Common Warrants under the Securities Act is not then effective or available, the holder may exercise the Common Warrant through a cashless exercise, in whole or